Mundipharma International Corp. Ltd., of Singapore, said it signed a deal with Orexo AB, of Uppsala, Sweden, granting Mundipharma’s network of companies exclusive global (ex-U.S.) rights to Zubsolv (buprenorphine and naloxone sublingual tablet) for use in opioid dependence. Under the terms, Orexo receives an up-front payment of €7 million (US$7.8 million) and, pending achievement of marketing authorizations and certain commercial milestones, also is entitled to receive further milestone payments as well as tiered royalties on future net sales.